MUC16 and ovarian carcinoma: In 2023, CAR-T cells secreting BiTEs were designed to target two tumor antigens highly expressed in ovarian cancer cells: the cell surface Muc16 (4H11) and the intracellular Wilms tumor 1 (ESK1).